A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer.

BACKGROUND

The unmet need for predictive biomarkers emerged from the unpredictable pattern of response to androgen signalling inhibition in metastatic castration-resistant prostate cancer (mCRPC). Here, we report on the testing of a previously identified candidate androgen signalling signature associated with response to androgen signalling inhibition.

PATIENTS AND METHODS

We report on the outcome of the first module of a phase II trial on abiraterone acetate (AA) followed by combination with dasatinib or sunitinib. Bone marrow biopsies (BMBs) with matched bone marrow aspirate and blood samples were collected at baseline and upon progression. End-points included assessment of a prespecified molecular signature consisting of nuclear androgen receptor (AR) overexpression, cytochrome P450, family 17, subfamily A, polypeptide 1 (CYP17) expression, and AR-C-/N terminal expression ratio of ≥0.8 by immunohistochemistry (IHC) in patients with benefit versus primary resistance to AA (i.e. progression within 4 months). Tumour markers also included v-ets avian erythroblastosis virus E26 oncogene homologue (ERG), androgen receptor splice variant (ARV7) by IHC and steroids by liquid chromatography-tandem mass spectrometry.

RESULTS

Of 170 patients accrued from 03/2011 to 02/2015, 44 (26%) were primary resistant to AA. Forty-eight patients had tumour infiltrated BMB at baseline. Pretreatment androgen signalling signature was linked to benefit from AA (p < 0.001). Presence of ERG was associated with benefit (p = 0.05), whereas nuclear ARV7 presence and 20 or more bone lesions at baseline with primary resistance (p = 0.04 and p = 0.0006, respectively).

CONCLUSION

Testing of a prespecified androgen signalling signature was highly supportive of its predictive value in maximal androgen deprivation strategies in mCRPC. Further validation is under way.

TRIAL REGISTRATION

ClinicalTrials.gov NCT01254864.

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement M.B., N.S., J.A.W., A.T., A.H., A.A., S.M.T., J.C.A., A.J.Z., P.C., J.W., P.T. and S.W. have no conflict of interest to declare. L.P. has received research funding from Pfizer, Roche/Genentech, Exelixis, and Merck and travel support from Merck. J.K. is an employee and owns stocks at Merck. S.S. has served as a consultant and/or as a member of the advisory board of Valeant, Dendreon, Apricity Health, Janssen, Polaris, Amgen, Bayer and Exelixis; has received research funding from Janssen, Bristol-Myers Squibb and AstraZeneca; has received honoraria from Compugen, Apricity Health, Janssen, Dendreon, Polaris, Parker Institute of Cancer Immunotherapy and Society for Immunotherapy of Cancer and has ownership interest with Apricity Health. N.T. has served as a consultant or as a member of the advisory board of Bristol-Myers-Squibb and Pfizer; has received research funding from Bristol-Myers-Squibb and honoraria from Bristol-Myers-Squibb and Pfizer and has participated in scientific advisory committees for Pfizer. C.J.L. has served as a consultant or as a member of the advisory board of Janssen; has received research funding from Bristol-Myers-Squibb, Janssen and Pfizer; has received honoraria from Janssen and has participated in scientific advisory committees for Pfizer. E.E. has received research grant support; served as a member of the advisory board and received honoraria and travel expense from Sanofi, Janssen, Astellas, Tolmar and Bayer.